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Abstract
Bitter taste stimuli are detected by a diverse family of G protein-coupled receptors (GPCRs) expressed in gustatory cells.
Each bitter taste receptor (TAS2R) responds to an array of compounds, many of which are toxic and can be found in nature.
For example, human TAS2R16 (hTAS2R16) responds to b-glucosides such as salicin, and hTAS2R38 responds to thiourea-
containing molecules such as glucosinolates and phenylthiocarbamide (PTC). While many substances are known to activate
TAS2Rs, only one inhibitor that specifically blocks bitter receptor activation has been described. Here, we describe a new
inhibitor of bitter taste receptors, p-(dipropylsulfamoyl)benzoic acid (probenecid), that acts on a subset of TAS2Rs and
inhibits through a novel, allosteric mechanism of action. Probenecid is an FDA-approved inhibitor of the Multidrug
Resistance Protein 1 (MRP1) transporter and is clinically used to treat gout in humans. Probenecid is also commonly used to
enhance cellular signals in GPCR calcium mobilization assays. We show that probenecid specifically inhibits the cellular
response mediated by the bitter taste receptor hTAS2R16 and provide molecular and pharmacological evidence for direct
interaction with this GPCR using a non-competitive (allosteric) mechanism. Through a comprehensive analysis of hTAS2R16
point mutants, we define amino acid residues involved in the probenecid interaction that result in decreased sensitivity to
probenecid while maintaining normal responses to salicin. Probenecid inhibits hTAS2R16, hTAS2R38, and hTAS2R43, but
does not inhibit the bitter receptor hTAS2R31 or non-TAS2R GPCRs. Additionally, structurally unrelated MRP1 inhibitors,
such as indomethacin, fail to inhibit hTAS2R16 function. Finally, we demonstrate that the inhibitory activity of probenecid in
cellular experiments translates to inhibition of bitter taste perception of salicin in humans. This work identifies probenecid
as a pharmacological tool for understanding the cell biology of bitter taste and as a lead for the development of broad
specificity bitter blockers to improve nutrition and medical compliance.
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Introduction
As the primary mechanism by which animals detect and evaluate
nutrients within foods and avoid ingesting toxins, the sense of taste
has a significant impact on food selection, nutrition, and health. For
example, the sense of taste in individuals is reported to correlate
with a variety of habits including dietary preference [1], alcohol
intake [2], smoking [3], and patient compliance with medical
regimens [4]. It is therefore highly desirable to manipulate bitter
taste perception and bitter taste receptors so that beneficial food
products and medicines may be rendered more palatable. Recently,
bitter taste receptors have been implicated in several aspects of
respiratory and gastrointestinal function, hinting at a broader
biological role for this receptor family [5,6,7,8,9,10,11]. Therefore,
bitter taste receptor modulation may also represent a new approach
for understanding the function of bitter taste receptors in non-
gustatory cells of airway epithelia, smooth muscle, and the intestine.
Bitter substances are recognized by, and bind to, a family of
taste receptors (TAS2Rs) that are expressed in bitter taste cells,
and initiate signaling via activation of intracellular heterotrimeric
G proteins [12,13,14,15,16,17]. TAS2Rs are phylogenetically
distinct from the canonical rhodopsin (class A) receptor family and
more closely related to the frizzled/smoothened family of GPCRs
[18]. There are at least 25 human full-length TAS2Rs, clustered
on 3 human chromosomes, which are highly divergent in
sequence, sharing between 30–70% amino acid homology [18].
Additionally, there are a large number of TAS2R pseudogenes
(over 30% of the human TAS2R repertoire), and there are more
than 80 single nucleotide polymorphisms (SNPs) among individual
TAS2R genes [19,20], several of which result in variation in the
range and intensity of various human bitter taste perceptions
[21,22,23,24]. Unlike most GPCRs, TAS2Rs recognize a diverse
variety of chemical moieties. While many bitter taste receptors
remain poorly characterized, the ligand specificity of several
TAS2Rs has been explored in detail. These include hTAS2R16,
which responds to b-glucosides such as salicin [25], hTAS2R38,
which responds to thiourea-containing molecules such as the drugs
phenylthiocarbamide (PTC) and 6-propyl-2-thiouracil (PROP)
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hTAS2R44), a closely related pair of receptors that transduce
the signal for the bitter taste of saccharin [23,26]. Despite the
diversity of chemicals recognized by TAS2Rs and the continued
interest in developing bitter blockers to mask the bitter taste of
drugs and certain foods, only a single synthetic inhibitor against
this class of GPCRs has been described to date [27]. The
identification of additional compounds that inhibit TAS2Rs may
help our understanding of the broader biological relevance of this
class of receptors, particularly if they utilize diverse mechanisms of
inhibition.
Probenecid (p-(dipropylsulfamoyl)benzoic acid) is an FDA-
approved inhibitor of the organic anion transporter Multidrug
Resistance Protein 1 (MRP1) and other organic anion transporters
[28,29]. Clinically, probenecid is used as a treatment for gout in
humans [30], acting as a uricosuric agent, and is also co-
administered with antibiotics and other chemotherapeutic agents
to improve their efficacy by reducing their excretion. Within the
laboratory, probenecid is commonly used to prevent the efflux of
calcium-sensitive fluorescent dyes during studies of cellular
calcium mobilization [31]. As such, many protocols for conducting
GPCR calcium influx assays recommend including probenecid to
facilitate dye loading. During the course of our studies of bitter
taste receptor signaling, we unexpectedly discovered that proben-
ecid inhibited the activation of the bitter taste receptor hTAS2R16
in response to its cognate ligand salicin. This activity occurred
rapidly and was independent of probenecid’s activity as a transport
inhibitor, suggesting that probenecid interacts with the receptor
rather than modulating downstream signaling processes. Consis-
tent with its rapid inhibition, hTAS2R16 point mutations can
suppress probenecid inhibition, suggesting a direct interaction with
hTAS2R16 and an allosteric inhibitory mechanism in which the
salicin and probenecid binding sites are distinct. Inhibition by
probenecid was also observed for additional TAS2R receptors,
including hTAS2R38 and hTAS2R43, but not for hTAS2R31 or
for other non-gustatory GPCRs tested. In human perceptual
studies, probenecid suppressed the bitter taste perception of
salicin, demonstrating a correlation between the in vitro findings of
probenecid inhibition and human bitter taste phenotype. The
discovery of probenecid as an inhibitor of bitter taste receptors and
human bitter perception offers insight into a molecular mechanism
for designing modulators of human taste perception for improved
food selection, nutrition, and health.
Results
Probenecid is an inhibitor of the hTAS2R16, hTAS2R38,
and hTAS2R43 bitter taste receptors
In order to study the cellular and molecular mechanisms of
human bitter taste perception, we used an in vitro calcium flux
assay in HEK-293T cells that monitors human bitter taste
receptor activation and inhibition. The addition of salicin
(3 mM) to HEK-293T cells transiently expressing hTAS2R16
and Ga16gust44 induces an increase in intracellular calcium levels
that is measured using a Ca
2+-activated fluorescent dye (Figure 1A).
Probenecid is commonly used to improve the cellular uptake of
various fluorescent dyes into cells and is typically recommended
for improving the sensitivity of GPCR calcium flux assays [31]. It
was therefore surprising that, upon a one hour pre-incubation with
1 mM probenecid (without washout), agonist responses of
hTAS2R16 were attenuated to near baseline levels (Figure 1A).
Using the calcium flux assay, we tested for probenecid inhibition
of other TAS2Rs. Similar to hTAS2R16, pre-incubation with
probenecid resulted in inhibition of hTAS2R38 activation by both
PTC and by PROP (Figure 1B and 1C), two different ligands of
hTAS2R38. hTAS2R43 and hTAS2R31 (formerly known as
hTAS2R44), two de-orphanized TAS2R receptors that share 25%
and 24% amino acid sequence identity with hTAS2R16
respectively, were also tested. Aloin induced an increase in
intracellular calcium in HEK-293T cells expressing hTAS2R43,
and this signal was almost completely inhibited by a 1 hour pre-
incubation with 1 mM probenecid (Figure 1D). In contrast, the
saccharin-induced calcium flux in cells expressing hTAS2R31 was
not inhibited by probenecid pre-treatment (Figure 1E). Because
the ligands used for testing each of these TAS2Rs represent diverse
structures (Figure 2), it is unlikely that probenecid is acting on the
ligands themselves. Addition of 1 mM probenecid or buffer
directly to transfected cells did not by itself result in any change
in intracellular calcium (Figure 1F). Our data suggest that
Figure 1. Inhibition of hTAS2R16, hTAS2R38, and hTAS2R43 by
probenecid. HEK-293T cells were transiently transfected with Ga16-
gust44 and the indicated TAS2R receptors in a 384-well microplate.
22 hours post-transfection, calcium influx was measured in cells
challenged with the indicated ligands in the presence (closed triangles)
or absence (open diamonds) of probenecid (1 mM; 1 hour pre-
incubation). Probenecid treatment completely attenuated (A) salicin-
dependent (3 mM) calcium influx by the hTAS2R16 receptor and (B)
PTC- (100 mM) and (C) PROP-dependent (30 mM) calcium influx by the
hTAS2R38 receptor. (D) Probenecid treatment similarly attenuated
aloin-induced (3 mM) hTAS2R43 signaling. (E) Probenecid treatment did
not inhibit saccharin induced signaling of hTAS2R31. (F) hTAS2R38
transfected cells challenged with probenecid or buffer alone (1 mM) did
not result in calcium influx, but do flux with the PTC control.
doi:10.1371/journal.pone.0020123.g001
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include hTAS2R16, hTAS2R38, and hTAS2R43.
We next examined whether probenecid could inhibit the
cellular activation of the non-gustatory GPCRs CXCR4 and
CCR5 when expressed in HEK-293T cells. The human
chemokine receptors CXCR4 and CCR5 are members of the
rhodopsin family of GPCRs, which are unrelated to the TAS2Rs
and are involved in inflammation, autoimmune disease, and viral
infection [32,33]. We observed no effect on RANTES-mediated
calcium mobilization by CCR5 and SDF-1a-mediated calcium
mobilization by CXCR4 upon pre-incubation with probenecid
(Figure 3A and 3B). We also tested the effect of probenecid on the
activity of the b2-adrenergic receptor (bAR), which is endoge-
nously expressed on HEK-293T cells [34]. Stimulation of
endogenous bAR co-expressed with Ga16gust44 resulted in an
increase in intracellular calcium upon stimulation with a cognate
adrenergic ligand (isoproterenol) that was not inhibited by a 1 hr
pre-incubation with probenecid (Figure 3C). Since bAR mobilizes
calcium in HEK-293T cells only in the presence of transfected
Ga16gust44, the inhibitory activity of probenecid is not the result
of action through Ga16gust44, which would have led to inhibition
of calcium influx. Probenecid also inhibited calcium mobilization
of hTAS2R38 in the canine cell line Cf2Th, suggesting that the
observed inhibition is not cell line specific (data not shown). While
probenecid inhibition of the G protein bc subunits cannot be
directly ruled out with the experiments conducted here, it is
unlikely since no effect on calcium mobilization was observed with
other GPCRs tested and since probenecid is commonly used to
enhance the Ca
2+ flux of diverse GPCRs signaling through diverse
G protein subunits. Thus, our data suggest that the inhibitory
effect of probenecid is specific to the TAS2R receptors and not to
downstream cellular components of G protein signaling.
Probenecid inhibition of bitter taste receptor activation is
rapid and does not involve MRP1
To determine the kinetics of inhibition by probenecid, we
measured the degree of inhibition of a model bitter taste receptor,
hTAS2R16, following 0, 5, and 30 minute pre-incubations with
probenecid (Figure 4A). Pre-incubation with probenecid for as
little as 5 minutes resulted in complete inhibition of hTAS2R16
signaling. Furthermore, even simultaneous injection of probenecid
with ligand gave measurable (.50%) inhibition (Figure 4A,
‘0 min’). These results demonstrate that the mechanism of action
of probenecid is extremely rapid, consistent with direct inhibition
of the receptors.
Probenecid is an FDA-approved inhibitor of MRP1 and other
organic anion transporters [29]. To determine whether MRP1
inhibition could explain probenecid’s mechanism of action, we
tested the ability of indomethacin, another MRP1 inhibitor that is
structurally unrelated to probenecid [28], to inhibit calcium
mobilization upon hTAS2R16 activation by salicin. We found that
the hTAS2R16 response to salicin was not inhibited by a 1 hr pre-
incubation with 1 mM indomethacin (Figure 4B). A similar lack of
inhibition using indomethacin was observed for the hTAS2R38
response to PTC (data not shown). Consistent with these results,
treatment with 1 mM chloroquine, another inhibitor of MRP1,
also failed to inhibit hTAS2R38 function (data not shown). The
observation that hTAS2R16 and hTAS2R38 are capable of
signaling in the presence of other MRP1 transporter inhibitors
suggests that probenecid’s mechanism of action does not occur
through MRP1 or related channels.
Pharmacology of probenecid
To assess the potency of probenecid, we measured probenecid
dose responses against hTAS2R16 (in the presence of 3 mM
salicin) and hTAS2R38 (in the presence of 300 mM PTC) and
calculated IC50 values of 292 mM and 211 mM respectively
(Figure 5A). To further characterize the mechanism of inhibition
by probenecid, we generated dose-response curves for salicin-
induced activation of hTAS2R16 in the presence of increasing
concentrations of probenecid. In the absence of probenecid, the
Figure 2. Structures of TAS2R agonists, probenecid, MRP1
inhibitors, and probenecid analogs used.
doi:10.1371/journal.pone.0020123.g002
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close to its reported value [25]. Upon the addition of increasing
concentrations of probenecid, we observe a dose-dependent
decrease in the maximum signal with little change in salicin
EC50 values (Figure 5B), a profile typical of non-competitive
allosteric inhibitors, which bind to a receptor site distinct from the
orthosteric ligand binding site [35]. A similar inhibition profile was
also observed for dose response curves of PTC-induced activation
of hTAS2R38 (Figure 5C).
To identify structural elements of the probenecid molecule that
contribute to TAS2R inhibition, we tested two probenecid
analogs: 4-sulfamoylbenzoic acid, comprising the core scaffold of
probenecid, and ethebenecid, containing ethyl groups rather than
propyl groups on the sulfamoyl group (Figure 2). Treatment with
1 mM 4-sulfamoylbenzoic acid demonstrated no inhibitory effect
on either hTAS2R16 or hTAS2R38 function (Figure 6). However,
treatment with 1 mM ethebenecid showed very small, but
consistent, inhibition of both hTAS2R16 and hTAS2R38,
suggesting that the inhibition of TAS2R function is due to specific
structural moieties of probenecid. The inability of 4-sulfamoyl-
benzoic acid and the reduced ability of ethebenecid to inhibit
TAS2R function suggests that the lengths of the acyl chains on the
sulfamoyl moiety are critical for the inhibitory action of
probenecid. This observation is consistent with hydrophobicity
playing an important role in the inhibitory function of probenecid.
Identification of hTAS2R16 residues required for
probenecid inhibition
To determine whether probenecid directly interacts with
hTAS2R16, we screened a random mutation library of
hTAS2R16 for mutations that caused a loss of inhibition by
probenecid. We identified two clones containing a total of three
mutations, N96T, P44T, and H113R, which were significantly
insensitive to probenecid inhibition while maintaining wild-type
levels of responsiveness to salicin (Fig. 7, p,0.001). Since one of
the probenecid insensitive clones contained two point mutations
(P44T and H113R), we also analyzed an additional clone
containing only the single point mutation H113R (Figure S1).
The H113R mutant demonstrates wild type calcium flux in the
presence of salicin and complete inhibition in the presence of
probenecid, strongly suggesting that P44T is the mutation that
confers probenecid insensitivity. These data thus define two amino
acid residues required for probenecid interaction and suggest a
direct interaction between probenecid and hTAS2R16 that is
consistent with probenecid’s rapid activity. Interestingly, both P44
and N96 are predicted to be located in or near the intracellular
regions of hTAS2R16 [36,37], consistent with our dose-response
profile of probenecid’s mechanism of action, which suggests
allosteric inhibition. Taken together, the presence of mutations in
hTAS2R16 that desensitize the receptor to probenecid but not the
ligand, the rapid mechanism of action of probenecid, and the
dose-response profiles of hTAS2R16 to salicin in the presence of
increasing amounts of probenecid suggest that probenecid
interacts directly with hTAS2R16 and behaves as a negative
allosteric modulator of hTAS2R16 function.
Probenecid can modulate human bitter taste perception
of the hTAS2R16 ligand salicin
Because multiple taste receptors, receptor alleles, and signaling
pathways are involved in human taste perception, taste receptor
function in cellular assays and taste perception in humans often do
not correlate [38]. To determine whether hTAS2R16 receptor
inhibition would translate into inhibition of bitter taste perception
in humans, we assessed whether probenecid could attenuate the
perceived bitterness intensity of the hTAS2R16 ligand salicin in
vivo. Salicin is an appropriate stimulus to confirm perceptual
efficacy because it interacts principally with the receptor
hTAS2R16, which has relatively few receptor polymorphisms
across subjects [24,25]. Fifteen tasters were asked to rate the
bitterness of a solution of 10 mM salicin on a 96 point general
labeled magnitude scale (gLMS) that ranges from ‘‘Barely
Detectable’’ to ‘‘Strongest Imaginable’’ [39,40]. Tasters were then
asked to rate the bitterness of salicin after rinsing with either
10 mM probenecid or, as a control bitter taste treatment, 8.1 mM
quinine HCl (matched to approximate the weak bitter taste of the
probenecid treatment to control for taste cross-adaptation effects).
Pre-treatment with probenecid led to a significant reduction in the
ability of subjects to perceive the bitter taste of salicin (Figure 8A,
p,0.05), which mirrored the effect of probenecid in our cellular
assay. Pre-treatment with the control solution, quinine, which is
not known to interact with hTAS2R16 [41], did not inhibit the
bitter taste of salicin. Importantly, 10 mM salicin evokes a
moderate level of bitterness as measured by the gLMS and is a
10-fold greater concentration than the EC50 seen in human
Figure 3. Non-Gustatory GPCRs are not inhibited by probenecid. HEK-293T cells were transiently transfected with Ga16gust44 and the
indicated GPCR receptors. In the case of the endogenously expressed bAR receptor, only Ga16gust44 was transfected. 22 hours post-transfection,
calcium influx was measured for cells that were challenged with the indicated ligands in the presence (closed triangles) or absence (open diamonds)
of probenecid (1 mM; 1 hour pre-incubation). Probenecid treatment did not attenuate calcium influx upon challenge of (A) CCR5 with 10 nM
RANTES, (B) CXCR4 with 10 nM SDF-1a, or (C) bAR with 10 mM isoproterenol.
doi:10.1371/journal.pone.0020123.g003
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probenecid is both statistically significant and perceptually robust.
We next tested for the ability of probenecid to inhibit the
perceived bitterness of saccharin, a well-characterized hTAS2R31
ligand [23,26]. Nine tasters were asked to rate the bitterness of a
250 mM saccharin solution (approximating moderate bitterness
intensity levels) before and after treatment with probenecid.
Because saccharin is a sweetener, we included the sweet taste
inhibitor lactisole in the solutions (to enable our subjects to focus
exclusively on the bitterness of saccharin). Probenecid treatment
did not inhibit the perceived bitterness of saccharin, consistent
with the results of our cellular assays, and the inhibitory effect of
probenecid on salicin was observed again both with and without
the addition of lactisole (Figure 8B). Taken together, our results
demonstrate that probenecid significantly inhibits human bitter
taste perception of a hTAS2R16 ligand, consistent with its
mechanism of action on the hTAS2R16 receptor in vitro.
Discussion
The human family of TAS2Rs is comprised of at least 25
GPCRs that are highly divergent in sequence, sharing about 30–
70% amino acid homology [18], which is reflected in the ability of
TAS2Rs to recognize a diverse variety of chemical moieties.
Despite this diversity, only a single inhibitor of these GPCRs has
been described to date [27]. Here we present evidence that an
FDA-approved therapeutic is an allosteric inhibitor of a subset of
human TAS2R receptors. The inhibitory properties of probenecid
were unexpected since probenecid is commonly used to improve
the cellular uptake of fluorescent dyes into cells to increase the
sensitivity of GPCR calcium flux assays [31]. Our results show that
probenecid can selectively inhibit the function of the bitter taste
receptors hTAS2R16, hTAS2R38, and hTAS2R43 in vitro, while
leaving intact the function of other bitter taste receptors and
GPCRs, including hTAS2R31, CXCR4, CCR5, and bAR.
Interestingly, the inhibition of multiple bitter taste receptors was
also observed for GIV3727, a recently described hTAS2R
antagonist [27]. Both probenecid and GIV3727 inhibit
hTAS2R43 but only weakly inhibit hTAS2R31 (if at all), while
each inhibitor has additional activity on a non-overlapping subset
of receptors. The ability of both compounds to inhibit subsets of
hTAS2Rs suggests that at least two different structural motifs may
exist within each of these subsets of hTAS2R receptors. A better
understanding of the structures of the TAS2Rs may reveal some of
these common structural motifs.
Although the interaction of probenecid with a TAS2R receptor
cannot be directly measured by binding or competition assays
because bitter taste ligands bind too weakly (high mMt om M
EC50s), our work provides several lines of evidence that the
mechanism of action for probenecid inhibition occurs by direct
binding to the hTAS2R16 receptor. First, analysis of hTAS2R16
point mutations define amino acid residues involved in probenecid
binding or signaling that result in decreased sensitivity to
probenecid while maintaining normal responses to the ligand
salicin. Second, mechanism of action studies for probenecid
against the hTAS2R16 receptor demonstrate rapid kinetics for
complete inhibition (within 5 minutes of probenecid treatment)
and near-instantaneous action for partial (.50%) inhibition,
consistent with an effect on an upstream signaling component,
such as the receptor itself. The effect of probenecid is also observed
in the presence of inhibitors against MRP transporters (reported
IC50, 100–150 mM) [42], which are responsible for probenecid’s
ability to increase fluorescent dye uptake. Probenecid is also
known to inhibit other proteins such as the pannexin1 hemi-
channels in taste bud cells (IC50, 150 mM) [43,44], but it is
unlikely that inhibition of such proteins would effect GPCR
signaling or explain the structural (point mutation) and mechanism
of action (rapid inhibition) studies here.
The identification of point mutations at residues 44 (P44T) and
96 (N96T) of hTAS2R16 that significantly suppress the ability of
probenecid to inhibit salicin activity help to define probenecid’s
mechanism of action on the receptor. Both mutations affect
probenecid activity without affecting salicin activity, suggesting an
allosteric mechanism with distinct sites on the receptor for salicin
and probenecid. This is in contrast to GIV3727, where mutations
in hTAS2R43 and hTAS2R46 that confer resistance to inhibition
alter both the specificity and activity of agonist compounds,
suggesting an overlapping binding site [27,45]. Nevertheless, P44
Figure 4. Probenecid inhibition of hTAS2R16 occurs rapidly
and is not dependent on the MRP1 transporter. (A) HEK-293T
cells were transiently transfected with hTAS2R16 and Ga16gust44.
22 hours post-transfection, calcium influx was measured for cells that
were challenged with 3 mM salicin in the presence of 1 mM probenecid
pretreatment for the indicated amount of time (0 min indicates co-
injection of salicin with probenecid). hTAS2R16 was completely
inactivated by 5 minutes of probenecid pretreatment. (B) HEK-293T
cells were transiently transfected with hTAS2R16 and Ga16gust44
followed by challenge with 3 mM salicin in the presence or absence of
the indicated compounds (1 mM, pretreatment for 60 minutes). The
MRP1 transporter inhibitor indomethacin did not inhibit hTAS2R16
function. Error bars represent standard errors (n=3).
doi:10.1371/journal.pone.0020123.g004
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interaction site, as these residues are not completely conserved
between the hTAS2Rs that are sensitive to probenecid (i.e.
hTAS2R16, hTAS2R38, and hTAS2R43 do not all contain P44
and N96 equivalents).
As suggested by structural studies of class A GPCRs [46] and
computational studies of TAS2Rs [27,47,48,49,50], the binding
site for bitter receptor ligands would be expected to be in the
transmembrane region of the receptor, with the site open to the
extracellular portion of the receptor. Based on structure
predictions, P44 and N96 are located in the first intracellular
loop and the C-terminal half of the third transmembrane domain,
respectively [36,37]. Previous studies have implicated N172,
located in the second extracellular loop of hTAS2R16, in the
activity of diverse agonists [24]. More recently, salicin ligand
docking studies and mutational analysis of hTAS2R16 demon-
strate the presence of at least 7 residues in TM3, TM5, and TM6
(distinct from P44 and N96) involved in ligand recognition for
hTAS2R16, with all residues located towards the extracellular face
of the receptor [47]. The disparate locations of these residues and
P44/N96, as well as the equivalence of the salicin response
between WT and P44T/N96T, is suggestive of distinct binding
sites for salicin and probenecid and point to an allosteric
mechanism of action for probenecid.
The intracellular location of the probenecid binding site
suggests that probenecid may potentially act by uncoupling G
proteins from the receptor. If so, probenecid may be a useful
reagent for understanding signal transduction for TAS2R
receptors. Additional mutational analysis to further define the
binding sites for probenecid and salicin on hTAS2R16 will be
important for a complete understanding of the molecular
mechanism of probenecid inhibition and may provide insight for
the rational design of effective bitter blockers.
It is interesting to note that well-known polymorphisms in
several TAS2Rs are found in the first intracellular loop, near the
location of the P44 mutation in hTAS2R16 that confers
probenecid resistance. For example, P49 of hTAS2R38 is located
in the first intracellular loop and is part of the well-known PAV
(taster) haplotype that confers sensitivity of individuals to PTC
[21]. Polymorphisms of a comparable residue, W35, in the
receptors hTAS2R43 and hTAS2R31 significantly modulate the
activity of the receptors with their respective ligands [23]. The
effect of mutations in the first intracellular loop of hTAS2R38,
hTAS2R43, and hTAS2R31 highlight the role of this domain as a
conserved modulator of TAS2R function.
Our studies using probenecid analogs suggest that inhibitor
hydrophobicity is important for the pharmacological activity of
probenecid. In particular, the propyl groups of probenecid may
Figure 5. Pharmacological mechanism of action of probenecid inhibition. (A) HEK-293T cells were transiently transfected with Ga16gust44
and hTAS2R16 or hTAS2R38. 22 hours post-transfection, cells were pre-treated with increasing amounts of probenecid for 1 hour followed by
challenge with 3 mM salicin or 300 mM PTC. (B) HEK-293T cells were transiently transfected with Ga16gust44 and hTAS2R16, pre-treated with
increasing amounts of probenecid for 1 hour, and then challenged with different concentrations of salicin. Error bars represent standard errors (n=4).
(C) HEK-293T cells were transiently transfected with Ga16gust44 and hTAS2R38, pre-treated with increasing amounts of probenecid for 1 hour, and
then challenged with different concentrations of PTC. Error bars represent standard errors (n=4).
doi:10.1371/journal.pone.0020123.g005
Figure 6. Differential effect of probenecid analogs on the activation of hTAS2R16 and hTAS2R38 receptors. HEK-293T cells were
transiently transfected with Ga16gust44 and the indicated TAS2R receptor. 22 hours post-transfection, calcium influx was measured after challenge
with (A) 3 mM salicin or (B) 100 mM PTC in the presence or absence of the indicated compounds (1 mM, pretreatment for 60 minutes). Error bars
represent standard deviations (n=6 for hTAS2R16; n=12 for hTAS2R38).
doi:10.1371/journal.pone.0020123.g006
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putative probenecid-binding site on hTAS2R16. The ability of
probenecid to cross the plasma membrane [51] due to its negative
charge at physiological pH and the hydrophobic character of
probenecid’s di-n-propyl groups, is consistent with the binding of
probenecid to a site on the intracellular face of the receptor, such
as one that blocks binding of a G protein to the receptor.
Finally, the ability of probenecid to completely inhibit the
cellular response to salicin in vitro provides a mechanistic
explanation for its ability to inhibit human bitter taste perception
of salicin in vivo. Future perceptual testing with a variety of diverse
bitter compounds will help to determine whether the inhibitory
effect of probenecid in vivo includes additional TAS2Rs.
Methods
Reagents
Salicin, probenecid, 6-n-propylthiouracil (PROP), 4-sulfamoyl-
benzoic acid, N,N-diethyl-4-sulfamoylbenzoic acid (ethebenecid),
chloroquine diphosphate, saccharin sodium salt hydrate, aloin,
quinine HCl, indomethacin, and isoproterenol were purchased
from Sigma (St. Louis, MO). Probenecid (Sigma P-8761) was
dissolved at 500 mM in 1 N NaOH and titrated to pH 7.0.
Phenyl-b-D-glucoside was purchased from TCI (Boston, MA).
SDF-1a and RANTES were purchased from Peprotech (Rocky
Hill, NJ), and phenylthiourea (PTC) was purchased from Alfa
Aesar (Ward Hill, MA).
Figure 7. Identification of hTAS2R16 residues required for probenecid inhibition. (A) HEK-293T cells were transiently transfected with wild
type hTAS2R16 and Ga16gust44. 22 hours post-transfection, calcium flux was measured for cells that were challenged with 3 mM salicin in the
presence (closed triangles) or absence (open diamonds) of probenecid (1 mM; 1 hour pre-incubation). Salicin response to mock transfected (vector
alone) HEK-293T cells is shown for comparison. (B, C) HEK-293T cells were similarly transfected with hTAS2R16 variants containing the mutations N96T
or P44T/H113R, and challenged with 3 mM salicin in the presence or absence of probenecid (1 mM; 1 hour pre-incubation). N96T and P44T/H113R
mutants showed decreased sensitivity to probenecid. A separate clone containing the single point mutant H113R was also tested to rule out this
residue (Figure S1). Error bars represent standard deviations (n=4).
doi:10.1371/journal.pone.0020123.g007
Figure 8. Suppression of human bitterness perception of salicin by probenecid. (A) 15 human subjects were asked to rate the bitterness
intensity of 10 mM salicin before (pre) and after (post) treatment with 10 mM probenecid or control treatment with 8.1 mM quinine HCl (QHCl) on a
general labeled magnitude scale (gLMS). Treatment with probenecid (black bars) significantly inhibited the perceived bitterness of salicin (p,0.05),
whereas a bitter taste control treatment with QHCl had no affect (white bars). (B) 9 human subjects were asked to rate the bitterness intensity of
10 mM salicin or 250 mM saccharin before (pre) and after (post) treatment with 10 mM probenecid or control treatment with 8.1 mM quinine HCl
(QHCl). Treatment with probenecid (black bars) significantly inhibited the perceived bitterness of salicin (p,0.05), whereas a control treatment with
QHCl had no affect (white bars). Probenecid failed to inhibit the bitterness of saccharin (in the presence of the sweet taste inhibitor lactisole (lac)t o
enable subjects to focus exclusively on the bitterness of saccharin). The inhibitory effect of probenecid on salicin was also observed in the presenceo f
lactisole, demonstrating that lactisole did not interfere with probenecid’s inhibition of perceived bitterness. At the concentrations used, salicin and
saccharin did not differ in their overall perceived bitterness. Error bars represent standard errors (SE).
doi:10.1371/journal.pone.0020123.g008
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hTAS2R16 (N172/H222 variant) [24], hTAS2R38 (PAV) [21],
hTAS2R43 (W35/H212) and hTAS2R31 (W35/M162/V227/
I240) [23] were cloned by PCR directly from genomic DNA isolated
from HEK-293T cells (DNeasy blood and tissue kit, Qiagen) and
TOPO cloned into pcDNA3.1D-V5His (Invitrogen) and pCAGGS
vectors. The first 45 amino acids of the rat somatostatin type 3
receptor, used for cell-surface targeting [25], were generated by
assembly PCR, and fusion proteins with bitter taste receptors were
generated by overlap-extension PCR. Point mutations of hTAS2R16
were generated by PCR and selected from a larger mutation library
of hTAS2R16 (Diversify Mutagenesis kit, Clontech) [52]. Rat
gustducin DNA was a kind gift of Liquan Huang (Monell Chemical
Senses Center). A Ga16 chimera containing the last 44 amino acids
of rat gustducin (Ga16gust44) was generated by overlap PCR. All
constructs were sequence verified.
Calcium flux assay
HEK-293T cells were transfected with hTAS2R expression
constructs using Lipofectamine 2000 (Invitrogen) in poly-lysine
coated, black 384-well plates with clear bottoms (Costar) and
incubated for 22 hours at 37uC. Growth media was removed and
cells were washed twice with HBSS containing 20 mM HEPES,
then loaded with a calcium indicator dye in HBSS containing
20 mM HEPES (Calcium 4 Assay kit, Molecular Devices) with or
without 1 mM probenecid. Cells were incubatedat 37uC for 1 hour
in the presence of both dye and probenecid, then moved to a
Flexstation II-384 (Molecular Devices) set for 32uC. After a 15-
minute temperature equilibration (without washout), indicated
compounds were injected (at t=,25 seconds) and fluorescence
was measured for 100 to 180 seconds, reading every 3 seconds.
Data sets were analyzed and represented as % over baseline signal
usingPrism5.0software(GraphPad Software,Inc).ForSchild plots,
replicates of raw calcium flux values were expressed as % over
baseline signal. The mean value at 36 seconds (correspondingto the
maximum flux signal) for each concentration of TAS2R ligand in
the presence of the indicated concentration of probenecid was
plotted against the log of ligand concentration. Data points were fit
using non-linear regression in GraphPad Prism.
Human perceptual testing
Subjects for perceptual studies were recruited and tested with a
protocol approved by the Office of Regulatory Affairs at the
University of Pennsylvania. Written consent was obtained on a
Regulatory Affairs-approved consent form. For the saccharin
stimulus and a parallel salicin stimulus, subjects were given
2.3 mM lactisole in mixture with the stimuli, to inhibit the sweet
taste of saccharin. Subjects were presented with the stimuli, either
30 ml of 10 mM salicin, 250 mM saccharin plus 2.3 mM lactisole,
or 10 mM salicin plus 2.3 mM lactisole in 40 ml medicine cups
(Baxter), and were asked to rate the bitterness intensity on a
general labeled magnitude scale (gLMS) that ranged from ‘‘Barely
Detectable’’ to ‘‘Strongest Imaginable’’ along a computerized
vertical 96 mm scale with magnitude labels spaced semi-
logarithmically. Subjects immersed the tongue (anterior 2 cm)
into the stimulus solution for five seconds while sealing their lips
around their tongue to control the area of stimulation. They were
then given a series of five cups containing 10 ml of either 10 mM
probenecid (dissolved in 1 N NaOH and pH adjusted to 7.4 using
1 M HCl) or a control stimulus (8.1 mM quinine HCl) and asked to
rinse with each cup for two minutes and expectorate after each
rinse. After rinsing, subjects were again presented with the same
stimulus tasted before treatment and asked to rate the bitterness
intensity from the anterior tongue. All stimuli were tested blindly
with both rinses in a 262 design. 8.1 mM quinine HCl was selected
as the control rinse to match the bitterness intensity of 10 mM
probenecid based on pilot testing with ten subjects to control for
bitter taste cross adaptation effects of the inhibitor.
Supporting Information
Figure S1 Analysis of hTAS2R16 H113R single mutant
for probenecid sensitivity. HEK-293T cells were transfected
with hTAS2R16 variant H113R followed by challenge with 3 mM
salicin in the presence or absence of probenecid (1 mM; 1 hour
pre-incubation). The H113R mutant demonstrated wild type
levels of sensitivity to probenecid and salicin. The light gray trace
represents inhibition of wild type hTAS2R16 in this experiment
and is shown for comparison.
(TIFF)
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